SpikImm Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

SpikImm General Information

Description

Developer of human monoclonal antibodies designed to target viruses, including the BK virus, providing broad and lasting protection for transplant patients. The company offers mAbs that improve transplant outcomes, patients' prognosis, and quality of life, enabling transplant recipients to experience enhanced protection and better overall health.

Contact Information

Website
www.spikimm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12-14 Rue Jean Antoine De Baif
  • 75013 Paris
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 12-14 Rue Jean Antoine De Baif
  • 75013 Paris
  • France
+33 01

SpikImm Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SpikImm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 31-Jul-2023 Completed Clinical Trials - General
2. Grant 15-Feb-2023 Completed Clinical Trials - General
1. Grant 16-Jan-2023 $16M Completed Clinical Trials - General
To view SpikImm’s complete valuation and funding history, request access »

SpikImm Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

SpikImm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12281155-B1 Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof Active 19-Jan-2024
WO-2025153707-A1 Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof Pending 19-Jan-2024
WO-2025153835-A1 Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof Pending 19-Jan-2024 C07K16/104

SpikImm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpikImm Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund
Truffle Capital Venture Capital Minority
To view SpikImm’s complete investors history, request access »

Ready to get started?

Request a free trial

SpikImm FAQs

  • When was SpikImm founded?

    SpikImm was founded in 2021.

  • Where is SpikImm headquartered?

    SpikImm is headquartered in Paris, France.

  • What is the size of SpikImm?

    SpikImm has 6 total employees.

  • What industry is SpikImm in?

    SpikImm’s primary industry is Drug Discovery.

  • Is SpikImm a private or public company?

    SpikImm is a Private company.

  • What is SpikImm’s current revenue?

    The current revenue for SpikImm is .

  • Who are SpikImm’s investors?

    Bpifrance and Truffle Capital have invested in SpikImm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process